Celcuity Inc.

NasdaqCM CELC

Celcuity Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -10.18

Celcuity Inc. Interest Coverage Ratio is -10.18 for the Trailing 12 Months (TTM) ending September 30, 2024, a 9.60% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Celcuity Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -11.27, a 37.57% change year over year.
  • Celcuity Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -18.05, a 39.48% change year over year.
  • Celcuity Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -29.82, a 99.96% change year over year.
  • Celcuity Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -68,220.15, a -56.32% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
NasdaqCM: CELC

Celcuity Inc.

CEO Mr. Brian F. Sullivan
IPO Date Sept. 20, 2017
Location United States
Headquarters 16305–36th Avenue North
Employees 55
Sector Health Care
Industries
Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Similar companies

MNOV

MediciNova, Inc.

USD 1.91

-4.02%

RZLT

Rezolute, Inc.

USD 4.72

-0.63%

ADAG

Adagene Inc.

USD 1.80

1.12%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

AVTE

Aerovate Therapeutics, Inc.

USD 2.47

-1.20%

CCCC

C4 Therapeutics, Inc.

USD 3.74

6.86%

ACRV

Acrivon Therapeutics, Inc. Common Stock

USD 5.56

0.91%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

ANAB

AnaptysBio, Inc.

USD 14.91

1.98%

HOWL

Werewolf Therapeutics, Inc.

USD 1.35

0.00%

CSBR

Champions Oncology, Inc.

USD 9.67

5.45%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email